In the Matter of
CNS Pharmaceuticals, Inc.

ORDER OF SUSPENSION OF TRADING

It appears to the Securities and Exchange Commission (the “Commission”) that the public interest and the protection of investors require a suspension in the trading of the securities of CNS Pharmaceuticals, Inc. (“CNS” or “the Company”) (CIK No. 0001729427) because of questions regarding the accuracy and adequacy of information in the marketplace about the company and its securities. Those questions relate to, among other things, statements made by CNS and others in press releases to investors issued between March 23, 2020 and April 13, 2020 concerning the Company’s business, including the status of development of a drug candidate labeled WP1122, the status of testing WP1122’s impact on COVID-19, and the ability to expedite regulatory approval of any such treatment.

CNS is a Nevada corporation whose principal place of business is Houston, Texas. The Company’s common stock is listed on the NASDAQ stock exchange under the symbol CNSP. As of April 21, 2020, CNS’s common stock had nineteen market makers.

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed Company.
THEREFORE, IT IS ORDERED, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed Company is suspended for the period from 9:30 a.m. EDT on May 4, 2020, through 11:59 p.m. EDT on May 15, 2020.

By the Commission.

Vanessa A. Countryman
Secretary